SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Multicenter performance evaluation of a transcription‐mediated amplification assay for screening of human immunodeficiency virus‐1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations
7 references·11 citing·34 second hop
Multicenter performance evaluation of a transcription‐mediated amplification assay for screening of human immunodeficiency virus‐1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations (2005)Multicenter performance evaluation of a t…High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan (2003)High throughput screening of …Trends in residual risk of transfusion‐transmitted viral infections in France between 1992 and 2000 (2002)Trends in residual risk of tr…Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window‐phase donations not detected by NAT (2002)Mathematic modeling of the ri…International application of the Incidence Rate/Window Period model (2002)International application of …Estimated risk of transfusion‐transmitted viral infections in Spain (2002)Estimated risk of transfusion…The Risk of Transfusion-Transmitted Viral Infections (1996)The Risk of Transfusion-Trans…The Cambridge Ancient History (1971)The Cambridge Ancient HistoryEvaluation of the Procleix Ultrio Elite Assay and the Panther-System for Individual NAT Screening of Blood, Hematopoietic Stem Cell, Tissue and Organ Donors (2016)Evaluation of the Procleix Ul…Évolutions technologiques en qualification biologique du don et leur impact sur le risque résiduel transfusionnel (2011)Évolutions technologiques en …Evaluation of the Roche cobas s 201 system and cobas TaqScreen multiplex test for blood screening: a European multicenter study (2008)Evaluation of the Roche cobas…Cost‐effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands (2008)Cost‐effectiveness of additio…Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201 (2008)Comparison of the analytical …Blood donor screening with nucleic acid amplification tests for human immunodeficiency virus, hepatitis C virus and hepatitis B virus (2008)Blood donor screening with nu…HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas® TaqScreen MPX test in seroconverting donors (2007)HIV-1, HCV and HBV seronegati…Evaluation of a multiplex human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand (2007)Evaluation of a multiplex hum…Impact of NAT on serological screening of transfusion‐transmitted agents (2006)Impact of NAT on serological …Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA (2006)Evaluation of a new molecular…Algorithm for recall of HIV reactive Indian blood donors by sequential immunoassays enables selective donor referral for counseling. (2006)Algorithm for recall of HIV r…Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing (2004)Transfusion-transmitted infections (2007)The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations (2003)Probability of Viremia with HBV, HCV, HIV, and HTLV among Tissue Donors in the United States (2004)Seroprevalence of human immunodeficiency virus in north Indian blood donors using third and fourth generation Enzyme linked immunosorbent assay (2013)IMPACT OF MULTIPLEX PCR IN REDUCING THE RISK OF RESIDUAL TRANSFUSION-TRANSMITTED HUMAN IMMUNODEFICIENCY AND HEPATITIS B AND C VIRUSES IN BURKINA FASO (2018)Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United States (1995)Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population (2002)Effect of a National Disaster on Blood Supply and Safety (2003)Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. (2003)Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States (2004)Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT) (2005)Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes (2009)One‐year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations (2009)Evaluation of two, commercial, multi‐dye, nucleic acid amplification technology tests, for HBV/HCV/HIV‐1/HIV‐2 and B19V/HAV, for screening blood and plasma for further manufacture (2012)10.1016/s0000-0000(03)47688-2 (2000)Risque résiduel de transmission du VIH, du VHC et du VHB par transfusion sanguine entre 1992 et 2002 en France et impact du dépistage génomique viral (2004)Residual risk of transfusion‐transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy (2005)The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection (1997)Health and economic impact of posttransfusion hepatitis B and cost‐effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union (2003)Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010 (2012)The Loeb Classical Library in 1954 (1955)Towards Greater Accuracy in Lexicostatistic Dating (1955)Ancient Egyptian Materials and Industries (1963)Gender, Police Arrest Decisions, and Notions of Chivalry (1983)Auditory processing skills and phonological representation in Dyslexic children (2004)Sumer and the Sumerians (2004)Hepatitis B virus blood screening: unfinished agendas (2006)Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors. (2008)Informative Dorfman Screening (2011)Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing (2005)Assessing the impact of HBV NAT on window period reduction and residual risk (2006)Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6‐year survey (2008)A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors (2005)
this work references cited by second hop

References

  • 1996The Risk of Transfusion-Transmitted Viral Infections1,865 cited
  • 1971The Cambridge Ancient History1,020 cited
  • 2002International application of the Incidence Rate/Window Period model150 cited
  • 2002Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window‐phase donations not detected by NAT117 cited
  • 2003High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan101 cited
  • 2002Trends in residual risk of transfusion‐transmitted viral infections in France between 1992 and 200098 cited
  • 2002Estimated risk of transfusion‐transmitted viral infections in Spain69 cited

Cited by

  • 2008Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 20152 cited
  • 2007Evaluation of a multiplex human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand29 cited
  • 2006Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA25 cited
  • 2007HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas® TaqScreen MPX test in seroconverting donors23 cited
  • 2008Cost‐effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

22 cited
  • 2008Evaluation of the Roche cobas s 201 system and cobas TaqScreen multiplex test for blood screening: a European multicenter study17 cited
  • 2011Évolutions technologiques en qualification biologique du don et leur impact sur le risque résiduel transfusionnel10 cited
  • 2006Algorithm for recall of HIV reactive Indian blood donors by sequential immunoassays enables selective donor referral for counseling.10 cited
  • 2016Evaluation of the Procleix Ultrio Elite Assay and the Panther-System for Individual NAT Screening of Blood, Hematopoietic Stem Cell, Tissue and Organ Donors9 cited
  • 2006Impact of NAT on serological screening of transfusion‐transmitted agents8 cited
  • 2008Blood donor screening with nucleic acid amplification tests for human immunodeficiency virus, hepatitis C virus and hepatitis B virus6 cited